Owners, management and financials
CVR: 43259326
Previous names: KemPharm Denmark A/S
DKK 123,335,000
Revenue
Net result: DKK 334,468,000
Zevra Therapeutics, Inc. (100%)
CVR · view owners
Timothy Sangiovanni
Board: Rahsaan Waleed Thompson (chair) and 3 members
CVR · view management
Active
Founded 13 May 2022
CVR · view overview
4 employees
Annual report 2025 · average
Director role ended: Raymond La Duane Clifton
CVR · 31/12/2025
View the full event history
Zevra Denmark A/S is a Danish company of the type Aktieselskab based in Frederiksberg, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named KemPharm Denmark A/S. The management consists of Timothy Sangiovanni. The board consists of Rahsaan Waleed Thompson (chair), Justin Andrew Renz, Thomas Weitemeyer and Timothy Sangiovanni. The company is owned by Zevra Therapeutics, Inc.. According to the 2025 annual report, the company had an average of 4 employees. In 2025, the company reported revenue of DKK 123,335,000 and a net result of DKK 334,468,000 compared with DKK -132,114,000 the year before. Equity in the 2025 report amounted to DKK 174,841,000.
Source: annual report 2025, Danish Business Authority
Zevra Denmark A/S has shown a remarkable turnaround in financial health, achieving a profit of 334,468,000 DKK in 2025 after experiencing significant losses in previous years. Revenue increased from 70,973,000 DKK in 2024 to 123,335,000 DKK in 2025, indicating a strong growth trajectory. However, the company faced challenges with negative equity in prior years, peaking at -159,627,000 DKK in 2024, which raises concerns about its financial stability. As a player in the research and experimental development sector, Zevra's recent profitability and revenue growth position it favorably, but ongoing monitoring of its equity and debt levels will be crucial for sustained success.
AI-generated summary · Generated 09/07/2026
Selskabets formål er forskning, udvikling, produktion, markedsføring, salg og/eller licensudstedelse af medicinske produkter til behandling af forskellige sygdomme samt hermed beslægtede aktiviteter efter bestyrelsens skøn.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 123.3 mio. | 334.5 mio. | 538.4 mio. | 174.8 mio. | 4 | |
| 202401/01/2024 – 31/12/2024 | 71 mio. | -132.1 mio. | 178.2 mio. | -159.6 mio. | 4 | |
| 202301/01/2023 – 31/12/2023 | - | -20.5 mio. | 189.1 mio. | -27.5 mio. | 6 |
Compared to 1.040 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of Zevra Denmark A/S is 43259326.
Zevra Denmark A/S is owned by Zevra Therapeutics, Inc..
The management of Zevra Denmark A/S consists of Timothy Sangiovanni.
The board of Zevra Denmark A/S consists of Rahsaan Waleed Thompson, Justin Andrew Renz and Thomas Weitemeyer, with Rahsaan Waleed Thompson as chair.
In 2025, Zevra Denmark A/S reported revenue of DKK 123,335,000.
Zevra Denmark A/S had an average of 4 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Zevra Denmark A/S has published its annual report for 2025. Revenue came to DKK 123,335,000, and the net result was DKK 334,468,000.
As of June 8, 2026, Justin Andrew Renz has joined the board of directors of Zevra Denmark A/S.
As of December 31, 2025, Timothy Sangiovanni has joined the board of directors of Zevra Denmark A/S.
As of December 31, 2025, Raymond La Duane Clifton has left the board of directors of Zevra Denmark A/S.
As of December 31, 2025, Timothy Sangiovanni is registered as adm. dir. of Zevra Denmark A/S.
As of December 31, 2025, Raymond La Duane Clifton has stepped down as adm. dir. of Zevra Denmark A/S.
Zevra Denmark A/S has published its annual report for 2024. Revenue came to DKK 70,973,000, and the net result was DKK -132,114,000.
As of July 16, 2025, Rahsaan Waleed Thompson has joined the board of directors of Zevra Denmark A/S.
As of July 16, 2025, Neil McFarlane has left the board of directors of Zevra Denmark A/S.
Zevra Denmark A/S has published its annual report for 2023. Gross profit came to DKK -12,548,000, and the net result was DKK -20,506,000.
As of March 25, 2024, Neil McFarlane has joined the board of directors of Zevra Denmark A/S.
As of March 25, 2024, Travis Clark Mickle has left the board of directors of Zevra Denmark A/S.
Zevra Denmark A/S has published its interim report for the period May 13, 2022 – December 31, 2022.
As of May 23, 2023, EY Godkendt Revisionspartnerselskab has been appointed auditor of Zevra Denmark A/S.
As of May 23, 2023, RSM DANMARK STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Zevra Denmark A/S.
On February 22, 2023, the company changed its name from KemPharm Denmark A/S to Zevra Denmark A/S.
As of May 13, 2022, RSM DANMARK STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Zevra Denmark A/S.
As of May 13, 2022, Thomas Weitemeyer has joined the board of directors of Zevra Denmark A/S.
As of May 13, 2022, Raymond La Duane Clifton has joined the board of directors of Zevra Denmark A/S.
As of May 13, 2022, Travis Clark Mickle has joined the board of directors of Zevra Denmark A/S.
As of May 13, 2022, Raymond La Duane Clifton is registered as adm. dir. of Zevra Denmark A/S.
As of May 13, 2022, is registered as an owner of Zevra Denmark A/S with an ownership share of 100%.
Zevra Denmark A/S was founded on May 13, 2022.
Companies in the same industry and area
CVR 40766383
CVR 42597333
CVR 46613139
CVR 44504332
CVR 43917897
